Targeted nanomedicines for treating pancreatic cancer
Engineered exosome mimetics as targeted biological nanomedicines for pancreatic cancer
This study is working on a new way to deliver cancer-fighting drugs directly to pancreatic cancer cells, which could help reduce side effects and make treatment more effective for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11041093 on NIH RePORTER |
What this research studies
This research focuses on developing engineered exosome mimetics that can specifically target pancreatic cancer cells. By utilizing a patented platform that identifies cancer-specific surface antigens, the study aims to create a precision nanomedicine that minimizes the harmful side effects of traditional chemotherapy drugs like gemcitabine and fluorouracil. The approach involves synthesizing vesicles derived from endosomes to deliver these drugs directly to cancer cells, potentially improving treatment efficacy and patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer, particularly those with non-resectable disease.
Not a fit: Patients with resectable pancreatic cancer or those not diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with pancreatic cancer.
How similar studies have performed: Other research has shown promise in using targeted nanomedicines for cancer treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Boston, United States
- Boston Children's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Moses, Marsha a — Boston Children's Hospital
- Study coordinator: Moses, Marsha a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.